Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid Tumors

REFERENCES

• Wicki S, Keisker A, Aebi C, Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy. Pediatr Blood Cancer. 2008;51:778–783.
   PubMed Web of Science ®Google Scholar
• Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadlephia: Lippincott Williams & Wilkins; 2006:1–13.
   Google Scholar
• Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents. 2000;16:107–111.
   PubMedGoogle Scholar
• Link H, Böhme A, Cornely OA, Antimicrobial therapy of unexplained fever in neutropenic patients et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol. 2003;82(Suppl 2):S105–S117.
   Google Scholar
• Ahmed N, El-Mahallawy HA, Ahmed IA, Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatr Blood Cancer. 2007;49:786–792.
   PubMed Web of Science ®Google Scholar
• Quezada G, Sunderland T, Chan KW, Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children wih cancer. Pediatr Blood Cancer. 2007;48:273–277.
   PubMedGoogle Scholar
• Ammann RA, Hırt A, Lüthy AR, Aebi C. Predicting bacteremia in children with fever and chemoyherapy-induced neutropenia. Pediatr Infect Dis J. 2004;23:61–67.
   PubMed Web of Science ®Google Scholar
• Paganini HR, Aguirre C, Puppa G, A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer. 2007;109:2572–2579.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Aviles CL, Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794–798.
   PubMed Web of Science ®Google Scholar
• Basu SK, Fernandez ID, Fisher SG, Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958–7966.
   PubMed Web of Science ®Google Scholar
• Hartel C, Deuster M, Lehrnbacher T, Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49:767–773.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415–3421.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Avilés CL, Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678–683.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Avilés CL, Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for ınvasive bacterial ınfection. J Clin Oncol. 2004;22:3784–3789.
   PubMedGoogle Scholar
• Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177–186.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Oltra A, Llorca C, Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer. 1996;32:1739– 1743.
   Google Scholar
• Kebudi R, Görgün O, Ayan I, Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001;36:434–441.
   PubMedGoogle Scholar
• Freifeld AG, Walsh T, Marshall D, Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165–176.
   PubMed Web of Science ®Google Scholar
• Oğuz A, Karadeniz C, Citak EC, Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol. 2006;23:245–253.
   PubMed Web of Science ®Google Scholar
• Kutluk T, Kurne O, Akyüz C, Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer. 2004;42:284–286.
   PubMed Web of Science ®Google Scholar
• Ariffin H, Ai CL, Lee CL, Abdullah WA. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health. 2006;42:781–784.
   PubMed Web of Science ®Google Scholar
• Müller J, Garami M, Constantin T, Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol. 2005;22:277–284.
   PubMed Web of Science ®Google Scholar
• Chastagner P, Plouvier E, Eyer D, Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med Pediatr Oncol. 2000;34:306–308.
   PubMedGoogle Scholar
• Hamidah A, Lim YS, Zulkifli SZ, Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J. 2007;48:615–619.
   PubMedGoogle Scholar
• Aksoylar S, Cetingül N, Kantar M, Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004;21:115–123.
   PubMed Web of Science ®Google Scholar
• Le Guyader N, Auvrignon A, Vu-Thien H, Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer. 2004;12:720–724.
   PubMed Web of Science ®Google Scholar
• Fass RJ, Gregory WW, D'Amato RF, In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters. Antimicrob Agents Chemother 1990;34:2256–2259.
   PubMed Web of Science ®Google Scholar
• Neu HC, Fu KP, Aswapokee N, Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother 1979;16:150–157.
   PubMed Web of Science ®Google Scholar
• Jones RN, Barry AL. Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium. Antimicrob Agents Chemother. 1983;24:293–296.
   PubMedGoogle Scholar
• Williams JD. Beta-lactamases and beta-lactamase inhibitors. Int J Antimicrob Agents. 1999;1(Suppl 1):S3–S7.
   Google Scholar
• Bodey G, Abi-Said D, Rolston K, Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 1996;15:625–634.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH. Safety and efficacy of cefoperazone plus sulbactam versus ceftazidime in the empiric treatment of febrile neutropenia. J Pharm Technol. 1998;14:63–69.
   Google Scholar
• Winston DJ, Bartoni K, Bruckner DA, Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 1998;26:576–583.
   PubMedGoogle Scholar
• Horiuchi A, Hasegawa H, Kageyama T, Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagn Microbiol Infect Dis. 1989;12:215S–219S.
   Google Scholar
• Görgün Ö, Ayan İ, Kebudi R, Solid tümörlü febril nötropenik hastalarda Sefoperazon + sulbaktam ile Seftazidimin karşılaştırılması. THOD. 1999;9:151–158.
   Google Scholar
• El-Haddad AMA. Comparison of sulbactam-cefoperazone versus piperacilline plus amikacin as empiric therapy in pediatric febrile neutropenic cancer patients. Curr Ther. Res. 1995;56:1094–1099.
   Google Scholar
• Lehrnbecher T, Foster C, Vazquez N, Therapy-induced alterations in host defence in children receiving therapy for cancer. J Pediatr Hematol Oncol. 1997;19:399–417.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Castagnola E, Caniggia M, Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology. 1988;55:489–500.
   Google Scholar
• Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176–189.
   PubMed Web of Science ®Google Scholar
• Mendes AV, Sapolnik R, Mendonça N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J). 2007;83(Suppl 2):S54–S63.
   Google Scholar
• Gaur AH, Flynn PM, Shenep JL. Optimum management of pediatric patients with fever and neutropenia. Indian J Pediatr. 2004;71:825–835.
   PubMedGoogle Scholar
• Hughes WT, Armstrong D, Bodey GP, 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751.
   PubMed Web of Science ®Google Scholar
• Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, Vancomycin use in pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000;21:48–50.
   PubMedGoogle Scholar
• Düzova A, Kutluk T, Kanra G, Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr. 2001;43:105–109.
   PubMed Web of Science ®Google Scholar